Navigation Links
Stroke Therapy with Corkscrew Device Most Beneficial, Study Suggests
Date:1/18/2010

border="0" cellspacing="0" cellpadding="0" class="text12px"> 
  • 24 patients who had no treatment entered the hospital with an NIHSS average score of 11.1 and left the hospital with an average score of 8.9, a 20 percent improvement. Two patients died. Patients in this group were those who sought treatment more than six hours after onset of stroke, or who were suffering from stroke caused by bleeding in the brain and therefore were not candidates for intervention.

Clot-busting drugs work by breaking up the clot to open up blood flow. In IV tPA, the drugs are infused intravenously through a standard IV. However, only some of the drugs make their way to the clot to break it up. IV tPA doesn’t require a specialist to administer it, and is the most widely available stroke treatment. IA tPA infuses the clot-busting drugs through a catheter (small tube) directly into the artery where the clot is located, meaning most of the drugs can quickly work to break up the clot. IA tPA must be administered by a physician who specializes in this treatment, such as an interventional radiologist. The clot-removing device is advanced on a wire through a catheter directly to the site of the clot. The device works like a corkscrew to hook into the clot and pull it out. This procedure also must be performed by a specialist.

“All of the treatment groups had improvement, but those in the clot-removing device-only group had the most significant improvement,” said Dr. Stambo. “In most of these patients, blood flow in the brain was re-established quicker than in patients who received the other treatments. If possible, people who show signs of suffering from stroke should get to a stroke center that of
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cancer, Heart Disease, Stroke, Diabetes, Chronic Pain and Depression Share a Major Pathology Factor
2. D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients
3. deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes
4. PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies
5. deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke
6. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
7. diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
8. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
9. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
10. Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
11. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Md. and RESEARCH TRIANGLE PARK, N.C. ... UTHR ) announced today that Roger Jeffs , ... provide an overview and update on the company,s business at ... in Boston, Massachusetts . The ... 3:30 PM Eastern Time, and can be accessed via a ...
(Date:4/30/2015)... 30, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, announced ... quarter of 2015 on May 7, 2015 after the ... will also host a conference call at 4:30 p.m. ... first quarter financial results. During the conference call, material ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Cytokinetics, Incorporated (Nasdaq: ... quarter of 2015 were $4.4 million, compared to $8.0 million ... for the first quarter was $8.9 million, or $0.23 per ... loss for the same period in 2014, of $8.7 million, ... March 31, 2015, cash, cash equivalents and investments totaled $117.5 ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer ... and production capability to serve biotechnology pharmaceutical clients. ... fulfillment continues to drive Nitto Avecia to enhance ... , In Fall 2014, Nitto Avecia ... at its Milford, MA facility, which is recognized ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... Oct. 5 ISTO Technologies, Inc. (ISTO), an  orthobiologics ... today the completion of patient enrollment in the Phase ... formulation of juvenile chondrocytes designed for the treatment of ... at two clinical sites. All patients enrolled in the ...
... the many pressing concerns of the day, fear of plague ... for those whose responsibility it is to combat bioterrorism, plague ... include scientists like medical researcher Steve Smiley, whose lab at ... will protect the public against weaponized forms of plague. The ...
... AMGN ) today announced that results from ... evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX or ... colorectal cancer (mCRC), respectively, were published online in the ... "Both studies demonstrated that Vectibix administered with chemotherapy significantly ...
Cached Biology Technology:ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 3Plague researchers race to beat bioterrorists 2Plague researchers race to beat bioterrorists 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 2Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 4Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 5Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 6Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 7Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 8Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 9Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 10Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 11
(Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
(Date:4/17/2015)... April 17, 2015 ... and technological advancement to drive biometric systems market ... 2020   According to a recently ... Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... register growth at CAGR of over 22% through ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2
... While many bacteria exist as aggressive pathogens, causing diseases ... toxic shock syndrome, others play a less malevolent role ... a new study, Cheryl Nickerson and her group at ... including Tom Van de Wiele and lead author Rosemarie ...
... , adds to our understanding of the role of stem and ... and treatment of cancer. , While stem cells are known to ... difficult to isolate. The new findings show that an antibody developed ... , Professor Pera, program leader for Stem Cells Australia and Chair ...
... Manchester have uncovered how the internal mechanisms in nerve ... avenues in the investigation of neurodegenerative diseases by analysing ... Prokop and his team at the Faculty of Life ... thin cable-like extensions of nerve cells that wire the ...
Cached Biology News:Beneficial bacteria may help ward off infection 2Beneficial bacteria may help ward off infection 3Beneficial bacteria may help ward off infection 4Beneficial bacteria may help ward off infection 5Stem cell research aids understanding of cancer 2Cell research opens new avenues in combating neurodegenerative diseases 2Cell research opens new avenues in combating neurodegenerative diseases 3
Agar, 500 g. Noble Agar.Moisture: < 10%, ash: < 1.6%, EEO (-mr): < 0.450 (pH 8.4). Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
MW5...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Biology Products: